Finance

Lists
Why is TDOC up 4,15%?
Dive Deeper
TDOC:NYSE
Teladoc Health Inc
USD 5,77
+4,15%
(+0,23) 1D
USD 5,82
+0,95% (+0,055)
After hours
Closed: 9 Okt., 16:00:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TDOC...
Open
USD 5,52
High
USD 5,80
Low
USD 5,48
Mkt. cap
1,05 mjd
Avg. vol.
3,52 m
Volume
4,19 m
52-wk high
USD 9,89
52-wk low
USD 4,40
EPS
-USD 0,99
Beta
2,14
Shares outstanding
181,68 m
No. of employees
5 k
Open
USD 5,52
High
USD 5,80
Low
USD 5,48
Mkt. cap
1,05 mjd
Avg. vol.
3,52 m
Volume
4,19 m
52-wk high
USD 9,89
52-wk low
USD 4,40
EPS
-USD 0,99
Beta
2,14
Shares outstanding
181,68 m
No. of employees
5 k
News stories
From web sources and news partners
Profile
Teladoc Health, Inc. is an American telemedicine and virtual healthcare company founded in 2002. Headquartered in New York City, its services include telehealth, employer-sponsored health plans, 24/7 care, mental health, diabetes and hypertension management, primary care, prescriptions, medical opinions, AI and analytics, telehealth devices and licensable platform services. The company uses telephone and videoconferencing software and mobile apps to provide on-demand remote medical care. Teladoc Health is active in over 175 countries, and is traded on the New York Stock Exchange. It is the first and largest telemedicine company in the United States, and has acquired numerous other companies including BetterHelp in 2015, Best Doctors in 2017, and Catapult Health in 2025. Wikipedia
About Teladoc Health Inc
CEO-
Employees5,12 k
Founded2002
Headquarters-
SectorHealth care
Analyst ratings
Based on 16 analysts giving stock ratings to TDOC in the past 3 months
Hold
Buy
4
Hold
12
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for TDOC in the last 3 months.
Highest
Current USD 5,77
USD 10,50 (+81,98%)
Average
USD 7,67 (+32,93%)
Lowest
USD 5,50 (-4,68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allen Lutz
Bank of America Securities
Buy
Maintained
USD 10,50
+82%
09/24/2026
Richard Close
Canaccord Genuity
Buy
Maintained
USD 10,00
+73,3%
08/31/2026
Jailendra Singh
Truist Financial
Hold
Maintained
-
-
09/01/2026
Michael Wiederhorn
Oppenheimer
Buy
Reiterated
USD 7,00
+21,3%
08/04/2026
Charles Rhyee
TD Cowen
Hold
Maintained
USD 6,00
+4%
08/03/2026
Daniel Grosslight
Citi
Hold
Maintained
USD 7,50
+30%
08/03/2026
Peter Warendorf
Barclays
Hold
Maintained
USD 7,00
+21,3%
08/03/2026
Stan Berenshteyn
Wells Fargo
Hold
Maintained
USD 6,00
+4%
07/30/2026
Brian Tanquilut
Jefferies
Hold
Maintained
USD 8,00
+38,6%
07/30/2026
David Grossman
Stifel Nicolaus
Hold
Maintained
USD 5,50
-4,7%
07/30/2026
Elizabeth Anderson CFA
Evercore ISI
Hold
Maintained
USD 7,50
+30%
07/30/2026
Sean Dodge
BMO Capital
Hold
Reiterated
USD 7,00
+21,3%
07/29/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
USD 10,00
+73,3%
07/29/2026
Ryan MacDonald
Needham
Hold
Reiterated
-
-
07/30/2026
David Larsen
BTIG
Hold
Reiterated
-
-
07/29/2026
Ryan Daniels
William Blair
Hold
Reiterated
-
-
07/29/2026
David Roman
Goldman Sachs
Buy
Maintained
USD 8,00
+38,6%
05/27/2026
Kevin Caliendo
UBS
Hold
Maintained
USD 6,00
+4%
05/15/2026
Lisa Gill
J.P. Morgan
Hold
Reiterated
USD 7,00
+21,3%
03/13/2026
George Hill
Deutsche Bank
Buy
Upgraded
USD 11,00
+90,6%
03/10/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
02/27/2026
Steven Valiquette
Mizuho Securities
Hold
Maintained
USD 6,00
+4%
02/26/2026
Jessica Tassan
Piper Sandler
Buy
Reiterated
USD 9,00
+56%
02/26/2026
Last report
29 Jul. 2026
Fiscal period
Q2 2026
-USD 0,20 / -USD 0,22
+10,84%beat
Revenue / Est. (USD)
606,93 m / 615,99 m
-1,47%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
626,44 m
642,27 m
613,84 m
606,93 m
Cost of goods sold
187,18 m
197,05 m
197,53 m
190,84 m
Cost of revenue
187,18 m
197,05 m
197,53 m
190,84 m
Research and development expenses
67,57 m
71,61 m
67,86 m
62,86 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
318,78 m
305,74 m
304,90 m
296,82 m
Operating expense
474,72 m
472,19 m
465,05 m
450,59 m
Total operating expenses
661,90 m
669,24 m
662,57 m
641,42 m
Operating income
-35,46 m
-26,97 m
-48,73 m
-34,50 m
Other non operating income
-815,00 k
378,00 k
-196,00 k
-2,19 m
EBT including unusual items
-50,22 m
-33,62 m
-60,84 m
-37,91 m
EBT excluding unusual items
-33,72 m
-24,59 m
-47,80 m
-35,32 m
Income tax expense
-715,00 k
-8,48 m
3,00 m
997,00 k
Effective tax rate
1,42%
25,21%
-4,92%
-2,63%
Other operating expenses
-
-
-
-
Net income
-49,51 m
-25,14 m
-63,84 m
-38,91 m
Net profit margin
-7,90%
-3,91%
-10,40%
-6,41%
Earnings per share
-0,19
-0,10
-0,28
-0,20
Interest and investment income
7,08 m
6,95 m
6,49 m
6,48 m
Interest expense
-4,53 m
-4,95 m
-5,37 m
-5,11 m
Net interest expenses
2,56 m
2,00 m
1,12 m
1,37 m
Depreciation and amortization charges
2,61 m
2,80 m
2,46 m
2,47 m
EBITDA
10,68 m
28,67 m
5,48 m
19,73 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme